BDTX - Company ID 0001701541
Black Diamond Therapeutics, Inc. trades as BDTX. In its fiscal 2025 annual report the company posted revenue of $70.00M and net income of $22.37B. This page tracks Black Diamond Therapeutics, Inc. through 470 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Insider trade | 4 | 2026-03-20 |
| Insider trade | 4 | 2026-03-20 |
The largest companies sharing Black Diamond Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Black Diamond Therapeutics, Inc. reported revenue of $70.00M for fiscal year 2025.
Yes. Black Diamond Therapeutics, Inc. reported net income of $22.37B in its latest fiscal year.